Impact News +++ Ayvens überzeugt mit starken Q3-Zahlen und kündigt Kapitalrückführung von 700 Millionen Euro an (Investing.com DE) +++ AYVENS Aktie +4,46%

CARDIOL Aktie

>CARDIOL Aktienkurs

0.977 EUR (Tradegate)

Ask: 0.99 EUR / 1010 Stück

Bid: 0.964 EUR / 1038 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CARDIOL Aktie über LYNX handeln

Intraday

1 Jahr

>CARDIOL Performance

1 Woche: -3,1%

1 Monat: +6,7%

3 Monate: -20,7%

6 Monate: +10,1%

1 Jahr: -41,3%

laufendes Jahr: -17,8%

>CARDIOL Aktie

Name:

CARDIOL THERAPEUTICS CL.A

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA14161Y2006 / A2PA9E

Symbol/ Ticker:

CT9 (Frankfurt)

Kürzel:

FRA:CT9, ETR:CT9, CT9:GR

Index:

Webseite:

https://www.cardiolrx.com..

Profil:

Cardiol Therapeutics Inc. is a clinical-stage biot..
>Volltext..

Marktkapitalisierung:

87.28 Mio. EUR

Unternehmenswert:

76.03 Mio. EUR

Umsatz:

EBITDA:

-25.18 Mio. EUR

Nettogewinn:

-23.67 Mio. EUR

Gewinn je Aktie:

-0.3 EUR

Schulden:

0.09 Mio. EUR

Liquide Mittel:

11.47 Mio. EUR

Operativer Cashflow:

-15.8 Mio. EUR

Bargeldquote:

2.27

Umsatzwachstum:

Gewinnwachstum:

-16.98%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CARDIOL

Letzte Datenerhebung:

30.10.25

>CARDIOL Kennzahlen

Aktien/ Unternehmen:

Aktien: 83.73 Mio. St.

Frei handelbar: 95.1%

Leerverk. Aktien: -

Rückkaufquote: -13.54%

Mitarbeiter: 22

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 554.93%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 11.52

PEG-Ratio: -0.37

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -162.37%

Eigenkaprendite: -276.41%

>CARDIOL Peer Group

Es sind 183 Aktien bekannt.

>CARDIOL Chart & Kurs - Tradegate

>CARDIOL News

21.10.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 (Newsfile)
	MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARC......

20.10.25 - 14:25	XFRA: CT9: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 AB/FROM ONWARDS 20.10.2025 14:14 CET...

20.10.25 - 08:42	XFRA: CT9: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CARDIOL THERAPEUTICS CL.A CT9 CA14161Y2006 BAW/UFN...

20.10.25 - 08:36	XFRA: INSTRUMENT_SUSPENSION - CA14161Y2006 (XETRA)
	Instrument ID [6186088] (CT9 - CA14161Y2006) suspended...

17.10.25 - 22:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 (Newsfile)
	MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARC......

15.10.25 - 13:45	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
	Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery....

11.08.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity′s 45th Annual Growth Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developi......

06.08.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis (Newsfile)
	Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with i......

22.07.25 - 21:03	Cardiol rises on database lockup for acute myocarditis therapy trial (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.07.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx in Acute Myocarditis (Newsfile)
	ARCHER is designed to assess the impact of CardiolRx on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis i......

29.05.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ......

27.05.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ......

29.04.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developin......

22.04.25 - 15:15	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
	Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors....

16.04.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis (Newsfile)
	Designed to assess the impact of CardiolRx on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-o......

01.04.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Year-End 2024 Update on Operations (Newsfile)
	Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis; results support advancing to th......

03.03.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing......

20.02.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, f (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on develo......

04.02.25 - 16:12	Cardiol Therapeutics to present at Oppenheimer Healthcare Conference (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

04.02.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the res......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Gelobte glaubt an die Kompetenz der Jury. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram